PegIFN/RBV

DRUG6 trials

Sponsors

Boehringer Ingelheim

Conditions

Hepatitis CHepatitis C, Chronic

Phase 2

Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)

CompletedNCT00774397

Boehringer IngelheimHepatitis C, Chronic

Start: 2008-10-31Updated: 2015-11-16

Phase 3

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)

CompletedNCT01297270

Boehringer IngelheimHepatitis C

Start: 2011-04-30End: 2014-04-30Updated: 2015-09-18

A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients

CompletedNCT01330316

Boehringer IngelheimHepatitis C

Start: 2011-07-31End: 2014-06-30Updated: 2016-06-30

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)

CompletedNCT01343888

Boehringer IngelheimHepatitis C

Start: 2011-04-30End: 2014-03-31Updated: 2015-09-18

Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)

CompletedNCT01399619

Boehringer IngelheimHepatitis C, Chronic

Start: 2011-09-30End: 2014-06-30Updated: 2016-08-29

A Phase III Study of BI201335 in Treatment-naive and Prior Relapser Patients With Chronic Hepatitis C Infection

WithdrawnNCT01608737

Boehringer IngelheimHepatitis C, Chronic

Start: 2012-09-30Updated: 2013-02-26

Related Papers

Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Naïve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial.

2016-05-262 citations

Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.

2016-05-011 citations

Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV.

2015-03-0112 citations

SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon α-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients

Antimicrobial Agents and Chemotherapy2014-04-0714 citations